Epoetin Alfa Articles
Amgen in firing line as Supreme Court OKs anemia drug lawsuits
28 February 2013
Hospira progresses biosimilar Epogen
11 January 2012
New guideline from ASH and ASCO recommends caution regarding ESA use in cancer patients
28 October 2010
US FDA advisory panel backs continued use of Amgen’s Aranesp and Epogen pre-dialysis, but calls for more studies
19 October 2010
US FDA to review use of anemia drugs from Amgen and Johnson & Johnson; Commissioner calls for shift in traditional testing methods
15 October 2010
FDA agrees plan requiring Amgen and J&J unit to educate doctors and patients on risks of anemia drugs
17 February 2010
Amgen's fourth quarter 2009 earnings slightly below consensus analyst’s expectations
26 January 2010
Court blocks Roche’s sales of Mircera in USA until 2014, as Amgen prevails in EPO patent dispute
23 December 2009
Cost-cutting helps Amgen lift 3rd quarter 2009 EPS 21%
22 October 2009
Biosimilar insulins and analogs set to erode $6.1 billion in brand sales in the USA and Europe by 2018
15 October 2009
Japan stock market week to May 4, 2009
5 May 2009
Falling profit on low sales for Amgen
27 April 2009
J&J 1st qtr hit by market drop; keeps guidance
15 April 2009
Hospira symp on assessing biosimilars
30 March 2009
New US DTC guidelines from PhRMA dismissed by leading Democrats
22 December 2008
Merck & Co unveils new biosimilars unit
15 December 2008
Stock Commentary - New York week to Oct 27, 2008
3 November 2008
Amgen's 3rd-qtr 2008 profit leaps to $1.16B
3 November 2008
Cochrane meta-analysis confirms ESA AE profile
13 October 2008
J&J's epoetin-alfa linked to deaths in stroke trial
22 September 2008
Hospira's Retacrit maintains Hb as well as Erypo
15 September 2008
FDA forces label-change for Amgen anemia drugs
1 September 2008
Amgen earnings down but outlook still up
4 August 2008
Roche's 1st-half net profit sees downturn
28 July 2008
Denosumab increases BMD in ADT patients
21 July 2008
Amgen and Ortho Bio settle antitrust suit
21 July 2008
EMEA recommends new warnings on epoetins
7 July 2008
Hospira launches Retacrit in UK
19 May 2008
New effort to curb DTC ads by US Democrats
12 May 2008
Amgen reports nearly flat 1st qtr
5 May 2008
Hematide: 18-month Hb maintenance
14 April 2008
Ortho modifies Procrit Rxing info
17 March 2008
Amgen sells Takeda Japanese rights to 13 drugs in a deal that could be worth up to $1.2B
11 February 2008
J&J's 4th-qtr 2007 sales jump 16.6%, EPS up 11%
28 January 2008
Stock Commentary - New York week to Dec 10, 2007
17 December 2007
Amgen in discussions to update US ESA labels
17 December 2007
Japan stock market week to Oct 29, 2007
5 November 2007
US insurer updates anemia drug policies
29 October 2007
Amgen wins in Roche Mircera patent suit
29 October 2007
Stada's Silapo gets CHMP thumbs up
29 October 2007
Charges hit J&J's third qtr; forecast raised
22 October 2007
Dosing begins in Ph III Hematide study
22 October 2007
Japan stock market week to October 1, 2007
8 October 2007
Stock Commentary - New York week to Sept 17, 2007
24 September 2007
FDA panel votes against restricting ESA dose
17 September 2007
Ortho reiterates confidence in Procrit
17 September 2007
UPDATE: Sandoz' biosimilar epoetin cleared in EU
10 September 2007
US oncology docs want CMS anemia drug review
10 September 2007
Sandoz gets EU approval for biosimilar epoetin alfa
10 September 2007
Stock Commentary - New York week to Aug 13, 2007
20 August 2007
Japan stock market week to August 13, 2007
20 August 2007
Stock Commentary - New York week to July 2, 2007
9 July 2007
France's drug spending up 1.4% says CNAM
25 June 2007
Amgen buys US renal specialist for $420M
11 June 2007
CMS moves quickly on ESA coverage limits
21 May 2007
Amgen's 1st-qtr 2007 net profits up 11%
30 April 2007
Hematide corrects anemia in CKD patients
30 April 2007
J&J's 1st-qtr profits slip 22% on Conor buy
23 April 2007
Stock Commentary - New York week to Mar 12, 2007
26 March 2007
Ortho Biotech reviews ESA Rxing info with FDA
5 March 2007
Stock Commentary - New York week to Jan 29, 2007
5 February 2007
Stock Commentary - New York week to Jan 15, 2007
22 January 2007
Roche submits more data for Mircera BLA
22 December 2006
Study finds role for J&J anemia drug in cancer
18 December 2006
Amgen responds to anemia drug controversy
11 December 2006
Roche's Mircera is first renal anemia drug to work on a twice-monthly dosing regimen
27 November 2006
Roche's CERA effective in CKD-based anemia
27 November 2006
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
